Gilead Sciences Inc. (GILD)
Gilead Sciences Stock Slips on Possible HIV Funding Cut
Pharmaceutical stock Gilead Sciences Inc (NASDAQ:GILD) is down 2.6% at $107.34, after news that domestic HIV prevention is under review by the Trump administration, and the Health and Human Services Department could significantly cut funds.
Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding
Gilead Sciences is the maker of Biktarvy and Descovy, two drugs used to treat the virus.
GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell?
Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the stock to investors.
Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025
Despite a correction to begin the year, there are a few pockets of the market that are working.
GILD vs. VRTX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive
Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.
Gilead Sciences, Inc. (GILD) Leerink Partners Global Healthcare Conference - (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) Leerink Partners Global Healthcare Conference Call March 11, 2025 10:40 AM ET Company Participants Cindy Perettie - Executive Vice President and Global Head, Kite Conference Call Participants Daina Graybosch - Leerink Partners Daina Graybosch I think we'll get started. Hi, everyone.
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
Here is how Gilead Sciences (GILD) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Buy Gilead Sciences (GILD) Stock at 52-Week Highs?
Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks.
Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?
Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Gilead Sciences, Inc. (GILD) TD Cowen 45th Annual Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) TD Cowen 45th Annual Healthcare Conference March 4, 2025 11:10 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.
